Plasma-Derived Apolipoprotein A-I Infusions Are Well-Tolerated, Acutely Increase Cholesterol Efflux Capacity
Human and recombinant apolipoprotein A-I (apoA-I) is the primary functional component of high-density lipoprotein, and has been shown to increase cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies.
Study Finds Blood Plasma Can Restore Brain Function
Results from a new study show that brain function can be restored by human blood plasma.
Reduced Mortality with Use of Four-Factor Prothrombin Complex Concentrates vs. FFP for Warfarin Reversal: Meta-Analysis
The optimal reversal strategy for urgent reversal of warfarin is unclear, but Canadian investigators conducted a systematic review of the clinical literature through December 2015, and identified five randomized clinical trials and eight observational studies for evaluation.
Topical Use of Fibrin Sealant Can Reduce Blood Loss and Need for Transfusion in Total Knee and Hip Arthroplasty
To assess the safety and effectiveness of topical administration of fibrin sealants on postoperative blood loss and blood requirements in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA), Chinese investigators searched electronic medical databases through February 2016 to identify randomized clinical trials (RCTs) for inclusion in a meta-analysis.
Recombinant Human Prothrombin Prevents Bleeding in Hemophilia A and B Mice
Both a plasma-derived human factor II (pdhFII) and an investigational recombinant human prothrombin (MEDI8111) dose-dependently decreased blood loss and bleeding time in hemophilia A mice, according to Swedish investigators at AstraZeneca’s CVMD IMED unit.
Blood Protein Therapeutics: It All Starts with the Plasma
The plasma donor is the first vital part of the process to produce safe and effective plasma protein therapeutics, and the industry prioritizes the safety and health of its plasma donors.
Plasma Exchange Effective in a Subset of Patients with Complex Regional Pain Syndrome
Usually developing following trauma, complex regional pain syndrome (CRPS) has been postulated to be associated with distal degeneration of small-diameter peripheral axons.
Grifols Invests in Alkahest to Develop Plasma-Based Products
Grifols has made a major equity investment in Alkahest to work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system.
Saving the Aging Brain: Grifols Attacks Alzheimer’s Disease Head-On
Grifols, the world’s third largest manufacturer of plasma-based therapeutics and a leader in immunohematology and transfusion medicine diagnostics, has been patiently developing a novel approach to treatment of AD, based on plasma exchange and replacement with donor human albumin.
In the Pipeline: Novel Plasma Proteins for Major Cardiovascular Disorders
OVER THE 70 years since biochemist Edwin Cohn and his Harvard Medical School laboratory first purified human albumin for use in severe burns and hemorrhagic trauma, nearly 30 therapeutic proteins from human plasma have been purified, proven safe and effective and approved for use. Most of these products (Table 1) are indicated as replacement therapies […]